Tacrolimus

Generic Name
Tacrolimus
Brand Names
Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
Drug Type
Small Molecule
Chemical Formula
C44H69NO12
CAS Number
104987-11-3
Unique Ingredient Identifier
Y5L2157C4J
Background

Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...

Indication

Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...

Associated Conditions
Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
Associated Therapies
-
Clinical Trials
Related News

Evaluation of the Impact of Tacrolimus-based Immunosuppression on Heidelberg Liver Transplant Cohort (HDTACRO): Study Protocol for an Investigator Initiated, Non-interventional Prospective Study

First Posted Date
2020-06-24
Last Posted Date
2020-06-24
Lead Sponsor
University Hospital Heidelberg
Target Recruit Count
100
Registration Number
NCT04444817
Locations
🇩🇪

Division of Visceral Transplantation, Department of General, Visceral andTransplantation Surgery, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany

Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients

First Posted Date
2020-05-27
Last Posted Date
2023-01-19
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
114
Registration Number
NCT04403321
Locations
🇨🇳

Peking union medical college hospital, Beijing, China

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

First Posted Date
2020-05-12
Last Posted Date
2024-10-17
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
45
Registration Number
NCT04384692
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

First Posted Date
2020-04-30
Last Posted Date
2024-07-11
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT04370301
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

The Effects of Microbiota Composition on Immunosuppression Protocols in Transplantation

First Posted Date
2020-04-24
Last Posted Date
2020-04-24
Lead Sponsor
Université Catholique de Louvain
Target Recruit Count
100
Registration Number
NCT04360031
Locations
🇧🇪

Cliniques universitaires Saint-Luc, Bruxelles, Belgium

Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury

First Posted Date
2020-04-10
Last Posted Date
2020-04-10
Lead Sponsor
Hospital Universitari de Bellvitge
Target Recruit Count
84
Registration Number
NCT04341038
Locations
🇪🇸

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

First Posted Date
2020-04-09
Last Posted Date
2024-06-27
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
59
Registration Number
NCT04339101
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

First Posted Date
2020-02-10
Last Posted Date
2024-03-06
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
70
Registration Number
NCT04262843
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.

Phase 2
Withdrawn
Conditions
Alzheimer Disease
Mild Cognitive Impairment
Interventions
Drug: Tacrolimus
First Posted Date
2020-02-10
Last Posted Date
2021-09-27
Lead Sponsor
Massachusetts General Hospital
Registration Number
NCT04263519

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

Phase 3
Terminated
Conditions
Kidney Failure
Interventions
Drug: Tacrolimus
Drug: Everolimus
First Posted Date
2020-02-06
Last Posted Date
2023-05-24
Lead Sponsor
Indiana University
Target Recruit Count
4
Registration Number
NCT04258423
Locations
🇺🇸

Indiana University, Indianapolis, Indiana, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy